QA Program Evaluation Research Tool CF-195, Effective

Similar documents
DETERMINING WHETHER AN ACTIVITY IS HUMAN SUBJECTS RESEARCH AS DEFINED BY FEDERAL REGULATIONS

IRB Policy 5 Research Activities

OHRP - Guidance on Research Involving Coded Private Information or Biological Specimens

Children s Hospital of Philadelphia Committees for the Protection of Human Subjects Policies and Procedures Research That Must Be Reviewed by the IRB

Determination of Human Subjects Research

IRB FREQUENTLY ASKED QUESTIONS. 1. Who must apply for human subjects review through the IRB (Institutional Research Board)?

DEFINING RESEARCH WITH HUMAN SUBJECTS - SBE

EXEMPT RESEARCH. Investigators should contact the IRB Office if there are questions about whether an amendment consists

INSTITUTIONAL REVIEW BOARD (IRB) PROCESS AND GUIDELINES FOR CONDUCTING RESEARCH AT ORANGE COAST COLLEGE

Department of the Navy Human Research Protection Program

COMMON RULE 2019 IMPLEMENTATION DATE: JANUARY 21, 2019

Protecting Human Subjects In Social-Behavioral-Educational Research:

Kate Gallin Heffernan (Chair) (617) Mark A. Borreliz (617)

INTERNATIONAL STANDARD ON ASSURANCE ENGAGEMENTS 3000 ASSURANCE ENGAGEMENTS OTHER THAN AUDITS OR REVIEWS OF HISTORICAL FINANCIAL INFORMATION CONTENTS

Protection of Research Subjects: The IRB Process

SYRACUSE UNIVERSITY HUMAN RESEARCH PROTECTION PROGRAM STANDARD OPERATING PROCEDURES

MDCH IRB REVIEW APPLICATION Authority: Code of Federal Regulations Title 45 Part 46

To IRB, or Not to IRB

IRBMED Seminar Series

Protection of Human Subjects Policies and Procedures

Revised August 28, 2018

Crossing the Line. When does innovative therapy become research?

Summary of Changes to Human Subjects Regulations: Effective January 21, 2019

Human Research Protection Program Institutional Review Board Procedure

The proposed rule is significant, and the requirements and exceptions are complex. Key provisions of the proposal are described below.

RESEARCH INVOLVING PRISONERS

REQUIRED INSTITUTIONAL REVIEW BOARD (IRB) EDUCATIONAL READING FOR FLETCHER SCHOOL RESEARCHERS APPLYING FOR EXEMPTION FROM IRB

Food Labeling: Revision of the Nutrition and Supplement Facts Labels and Serving Sizes of

OHRP Guidance on the Involvement of Prisoners in Research

TITLE: Obtaining Informed Consent of Non-English Speakers SOP #: CON-101 (formerly SM-507) Page: 1 of 7 Effective Date: 1/14/2016

Guidance on Returning Research Results to Subjects

Assurance Engagements Other than Audits or Review of Historical Financial Statements

This SOP applies to all IRB administrative staff, members and investigators. IRB members, administrative staff and investigators.

Re: National Bioengineered Food Disclosure Standard; Proposed Rule; Request for Comments, 83 Fed. Reg (May 4, 2018), Docket No.

International Pharmaceutical Aerosol Consortium on Regulation and Science

Progress from the Patient-Centered Outcomes Research Institute (PCORI)

Withdrawal of Proposed Rule on Supplemental Applications Proposing Labeling Changes for

DEPARTMENT OF VETERANS AFFAIRS SUMMARY: The Department of Veterans Affairs (VA) proposes to amend its medical

Human Subject Institutional Review Board Proposal Form

ANDA Submissions Refuse to Receive for Lack of Proper Justification of Impurity Limits Guidance for Industry

COLUMBIA UNIVERSITY INSTITUTIONAL REVIEW BOARD GUIDANCE ON ELECTRONIC INFORMED CONSENT

A proposal for collaboration between the Psychometrics Committee and the Association of Test Publishers of South Africa

PROTECTION OF HUMAN SUBJECTS

Agency Information Collection Activities; Submission for Office of Management and Budget

Guidance - IDE Early/Expanded Access for Devices

Establishment of a New Drug Code for Marihuana Extract. AGENCY: Drug Enforcement Administration, Department of Justice.

FDA s Evidence-Based Review System

Informed Consent Procedures and Writing Informed Consent Forms

Final Rule Material: Changes to Exempt Categories

Alignment of FSMA with Existing Food Safety Programs International Citrus & Beverage Conference

Purpose of this Document

SUBJECT: SJMHS Institutional Review Board(s): Vulnerable Populations - Research Involving Prisoners

Final Rule Material: New and Revised Definitions

The AAA statement on Ethnography and Institutional Review Boards (2004) provides a useful working definition:

Use of Standards in Substantial Equivalence Determinations

TOBACCO PRODUCT OR MEDICAL PRODUCT?

If the HPTN 082 protocol is amended in the future, this Letter of Amendment will be incorporated into the next version.

NIH NEW CLINICAL TRIAL REQUIREMENTS AND FORMS-E

NCI CIRB Independent Model studies is described herein.

510(k) submissions. Getting US FDA clearance for your device: Improving

EUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL. PHARMACEUTICAL COMMITTEE 21 October 2015

DISCLOSURE OF ALCOHOL AND SUBSTANCE/DRUG ABUSE RECORDS. This Policy describes permissible disclosures of Alcohol and Substance/Drug Abuse Records.

FDA issues long-awaited final guidance on when a device modification requires a new 510(k)

IAASB Exposure Draft, Proposed ISAE 3000 (Revised), Assurance Engagements Other Than Audits or Reviews of Historical Financial Information

TENNESSEE STATE UNIVERSITY HUMAN SUBJECTS COMMITTEE

Auditing Standards and Practices Council

Re: Docket No. FDA D Presenting Risk Information in Prescription Drug and Medical Device Promotion

Archived Content. This content was archived on June 24, 2013.

IRB for Humanists. Naomi E. Coll, MPH, CPH, CIP Manager of Research Integrity

Statistical Analysis Plans

8 December Mr. Ken Siong Technical Director International Ethics Standards Board for Accountants 529 Fifth Avenue New York NY 10017, USA

Human Research Participant Protection Program

Distinguishing a Program Evaluation (PE) From a Research Project (RP): A Primer

July 3, Re: Proposed Rule: National Bioengineered Food Disclosure Standard. 83 FR (May 4, 2018). Docket No. AMS-TM

Environmental, Health and Safety

Assurance Engagements Other Than Audits or Reviews of Historical Financial Information

Taylor C. Wallace, PhD, CFS, FACN, March 22, 2018

C 178/2 Official Journal of the European Union

DRAFT GUIDANCE DOCUMENT Comparative Bioavailability Standards: Formulations Used for Systemic Effects

International Framework for Assurance Engagements

Business Impact Analysis

Application for Ethical Approval of Research Proposals

[LIMITED ENGLISH PROFICIENCY PLAN] Table of Contents

US H.R.6 of the 115 th Congress of the United States Session

Manual for Expedited Reporting of Adverse Events to DAIDS Version 2.0 January 2010

EHR Developer Code of Conduct Frequently Asked Questions

NDA NDA APPROVAL

INSTITUTIONAL REVIEW BOARD

Student Guide To Ethics Review For Research Involving Human Subjects

Update on the Clinical Outcome Assessment Qualification Program and COA Compendium

WHO Framework Convention on Tobacco Control

LEAF Marque Assurance Programme

INFORMATION FOR RESEARCHERS REQUESTING DATA FROM THE NHVPR

DRAFT (Final) Concept Paper On choosing appropriate estimands and defining sensitivity analyses in confirmatory clinical trials

Teva Pharmaceuticals USA Attention: Scott D. Tomsky Vice President, US Generics Regulatory Affairs 425 Privet Road Horsham, PA 19044

Overhauling The 510(k) Process

PROPOSED WORK PROGRAMME FOR THE CLEARING-HOUSE MECHANISM IN SUPPORT OF THE STRATEGIC PLAN FOR BIODIVERSITY Note by the Executive Secretary

3/6/2017-6/15/2017 Permission to Take Part in a Human Research Study Page 1 of 6

SUMMARY: The Food and Drug Administration (FDA) is requesting public input on updated

Principles of publishing

Transcription:

COMPARISON OF THE CHARACTERISTICS OF RESEARCH, QUALITY IMPROVEMENT, AND PROGRAM EVALUATION ACTIVITIES RESEARCH QUALITY IMPROVEMENT PROGRAM EVALUATION COMMENTS INTENT Intent of project is to develop or Intent of project is to improve a practice Intent of project is to improve a specific contribute to generalizable or process within a particular institution or program knowledge (e.g., testing ensure it confirms with expected norms hypotheses) DESIGN MANDATE or ENDORSEMENT EFFECT ON PROGRAM OR PRACTICE EVALUATED POPULATION BENEFITS DISSEMINATION OF RESULTS Designed to develop or contribute to generalizable knowledge; may involve randomization of individuals to different treatments, regimens, or processes Activities not mandated by institution or program Findings of the study are not expected to directly affect institutional or programmatic practice Usually involves a subset of individuals - universal participation of an entire clinic, program, or department is not expected; generally, statistical justification for sample size used to ensure endpoints can be met Participants may or may not benefit directly benefit, if any, to individuals incidental or delayed Intent to publish or present generally presumed at the outset of project as part of professional expectations, obligations; dissemination of information usually occurs in research/scientific publications or other research/scientific fora; results expected to develop or contribute to generalizable knowledge by filling a gap in Not designed to develop or contribute to generalizable knowledge; generally does not involve randomization to different practices or processes Activity endorsed or mandated by the institution or clinic as part of its operations Findings of the study are expected to directly affect institutional practice and identify corrective action(s) needed Information on all or most receiving a particular treatment or undergoing a particular practice or process expected to be included; exclusion of information from some individuals significantly affects conclusions. Initial work can be limited to a smaller subgroup to identify and plan for implementation or feasibility etc. with the expectation that the practice or process will be extended to the broader population. Participants expected to benefit directly from the activities Dissemination of information may occur in quality improvement publications/fora; when published or presented to a wider audience, the intent is to suggest potentially effective models, strategies, assessment tools or provide benchmarks or base rates rather than to develop or contribute to generalizable knowledge. Any publication should footnote that the project was carried out as QA and did not meet the definition of Not designed to develop or contribute to generalizable knowledge; does not involve randomization of individuals, but may involve comparison of variations in programs Activity endorsed or mandated by the program, usually its funder, as part of its operations Findings of the evaluation are expected to directly affect the conduct of the program and identify improvements Information on all or most participants within or affected by receiving a particular treatment or undergoing a particular practice or process expected to be used; exclusion of information from some individuals significantly affects conclusions No benefit to participants expected; evaluation concentrates on program improvements or whether the program should continue Intent to publish or present generally presumed at the outset of the project; dissemination of information to program stakeholders and participants; may be publicly posted (e.g., website) to ensure transparency of results; when published or presented to a wider audience, the intent is to suggest potentially effective models, strategies, assessment tools or provide benchmarks or base rates rather than to develop or contribute to generalizable

scientific knowledge or supporting, refining, or refuting results from other research studies research per DHHS regs. CLINICAL SETTINGS USE OF PLACEBO Use of placebo may be planned Comparison of standard treatments, practices, techniques, processes placebo would NOT be used DEVIATION FROM STANDARD PRACTICE May involve significant deviation from standard practice Unlikely to involve significant deviation from standard practice knowledge. Any publication should footnote that the project was carried out as QA and did not meet the definition of research per DHHS regs. Definitions: Human Subjects Research For the purposes of this policy human subject research is defined as an activity that meets the definition of research and involves human subjects as defined either by the Common Rule or by FDA regulations. Research A systematic investigation, including development, testing and evaluation, designed to develop or contribute to generalizable knowledge. Activities that meet this definition may be funded or unfunded, or may be conducted as a component of another program not usually considered research. For example, demonstration and service programs may include evaluation components, and may constitute research activities under this definition. For the purposes of this policy, a systematic investigation is an activity that involves a prospective study plan which incorporates data collection, both quantitative and qualitative, and data analysis to answer a study question. Investigations designed to develop or contribute to generalizable knowledge are those designed to draw general conclusions (i.e., knowledge gained from a study may be applied to populations outside of the specific study population), inform policy, or generalize findings. Research as defined by FDA regulations means any experiment that involves a test article and one or more human subjects, and that either must meet the requirements for prior submission to the Food and Drug Administration under section 505(i) or 520(g) of the Federal Food, Drug, and Cosmetic Act, or need not meet the requirements for prior submission to the Food and Drug Administration under these sections of the Federal Food, Drug, and Cosmetic Act, but the results of which are intended to be later submitted to, or held for inspection by, the Food and Drug Administration as part of an application for a research or marketing permit. The terms research, clinical research, clinical study, study, and clinical investigation are synonymous for

purposes of FDA regulations. [21 CFR 50.3(c), 21 CFR 56.102(c)] Experiments that must meet the requirements for prior submission to the Food and Drug Administration under section 505(i) of the Federal Food, Drug, and Cosmetic Act means any use of a drug other than the use of an approved drug in the course of medical practice. [21 CFR 3 12.3(b)] Experiments that must meet the requirements for prior submission to the Food and Drug Administration under section 520(g) of the Federal Food, Drug, and Cosmetic Act means any activity that evaluates the safety or effectiveness of a device. [21 CFR 812.2(a)] Any activity in which results are being submitted to or held for inspection by FDA as part of an application for a research or marketing permit is considered to be FDA-regulated research. [21 CFR 50.3(c), 21 CFR 56.102(c)]. Human Subject as defined by the Common Rule A living individual about whom an investigator (whether professional or student) conducting research obtains: 1. data through intervention or interaction with the individual, or 2. identifiable private information. Intervention includes both physical procedures by which data are gathered (for example, venipuncture) and manipulations of the subject or the subject's environment that are performed for research purposes. Interaction includes communication or interpersonal contact between investigator and subject. Private information includes information about behavior that occurs in a context in which an individual can reasonably expect that no observation or recording is taking place, and information which has been provided for specific purposes by an individual and which the individual can reasonably expect will not be made public (for example, a medical record). Private information must be individually identifiable (i.e., the identity of the subject is or may readily be ascertained by the investigator or associated with the information) in order for obtaining the information to constitute research involving human subjects.] Human Subject as Defined by FDA Regulations Any individual who is or becomes a subject in research; either as a recipient of the test article or as a control. A subject may be either a healthy human or a patient. In the case of a medical device, a human subject/participant is also means a human on whose

specimen an investigational device is used. Research Compared with Quality Improvement/Quality Assurance or Program Evaluation The touchstones for separating quality improvement and program evaluation from research concern the intent of the project, the degree to which results are designed to contribute to generalized knowledge, the effect of results on program practice or processes, and the scope of dissemination of results. In general many research methods may also be used in quality improvement and program evaluation projects. In clinical settings the use of a placebo or significant deviation from standard of care is unlikely to be viewed as quality improvement or program evaluation. Quality Improvement: Quality improvement activities are generally pursued in order to evaluate existing local practices with a goal of documenting and correcting deficiencies. If the goal of a project is to determine success/effectiveness or failure of a given program or process and the information gained from that evaluation is used to improve the program, this is not considered research involving human subjects, even when information is collected in a systematic way, because the results of this type of activity are not considered applicable to populations other than those under evaluation. Publication or presentation is allowed but results must not be described as or inferred to be generalizable to a broader population, i.e., they may not be described as research results. If, however, quality improvement activities involving human subjects are used to test novel services or programs for effectiveness and are presented in a more global fashion or applied to a broader population they should be considered research involving human subjects. For example: efforts to assess current clinic practices within a hospital (i.e., local) and to modify those practices to improve effectiveness would not meet the federal definition of research even though the evaluations collected data in a systematic manner. Presentation within the local environment (i.e., to the hospital staff) and publication of the results would be acceptable, so long as results are described as quality improvement and application of the findings is clearly limited to the location where they were found. If, however, results are presented outside of the local environment at a national meeting or published in a journal using language that seeks to generalize results beyond the locality of the project or that describes the study as research, the study would be considered human subject research and need review by the relevant IRB. Another

example of research subject to IRB review would be efforts to assess current clinical practices of a number of local, unrelated entities and the aggregation of all these efforts to support a change in clinical practice beyond the local. As to each local organization, the assessment might constitute quality improvement, but when the results are aggregated to support a more generalizable recommendation, OHRP has determined that the aggregation of separate quality improvement activities constitutes research. Program Evaluation: Program evaluation is the inquiry into past, present, and potential programs to understand or clarify their needs, working processes, or impact. When the purpose of the evaluation is to provide feedback to the program and/or funder to improve that program, the activity is not human subject research and does not need IRB review and/or approval. Presentation of findings to the program and its funders and publication of the results would be acceptable, so long as results are described as program evaluation efforts and are clearly limited to the program to which they apply and are not described as research. Program evaluation is considered human subjects research when the intent is to contribute to generalizable knowledge. If results are presented or published using language that seeks to generalize results beyond the program studied, the study would be considered human subject research and would need review by the relevant IRB. Examples of evaluations that would be considered research and need human subjects review include: 1) dissemination of evaluations connected to outcomes to affect the development or implementation of other programs similar in nature; and 2) evaluation undertaken to test a new, modified, or previously untested intervention, service, or program to determine whether it is effective and can be used elsewhere. Even when activities constitute quality improvement or program evaluation, it is expected that the gathering of data from human subjects through direct or indirect interaction will done with the highest level of regard for the protection of human subjects and in accord with ethical standards. The Principal Investigator should use this tool and the accompanying guidance to evaluate each project. If any of the boxes in the research column are checked then the project must be submitted to COMIRB / HSRC for review and approval. If the tool indicates that this is quality improvement (QI) or program evaluation (PE) only the signatures detailed below should be obtained

Acknowledgment I have appropriately used this tool to evaluation my project entitled: By my signature below, I affirm that this project meets the definition of: [Circle the appropriate term] Quality Improvement Program Evaluation I certify that I will conduct my project in compliance with all federal, state and local laws and policies. If during the course of the project it is amended in such a way as to meet the definition of human subject research under 45 CFR 46 or 21 CFR 56 then I understand that I must submit to COMIRB for review prior to continuing the project. Signature of Principal Investigator Date Signature of Mentor Date (if applicable) I have reviewed this project proposal and determine that meets the criteria for quality improvement or program evaluation as outlined above and is an appropriate project to be conducted within this Division/ Department/ School/. Signature of Appropriate Authority (or their designee) Date Print Name of Appropriate Authority Position

(or their designee) Guidelines: This document should be retained with the project file and referenced as needed. If you have any questions or concerns that the project may include a research component, submit to COMIRB using the appropriate forms available on the website: COMIRB: http://www.ucdenver.edu/academics/research/aboutus/comirb/pages/comirb-home.aspx